FROM SCIENCE TO CLINICAL PRACTICE: ADHD ACROSS THE LIFESPAN

JANUARY 13-15, 2017
THE MAYFLOWER HOTEL
WASHINGTON, D.C.

JOINTLY SPONSORED BY:
Dear APSARD Colleagues:

Welcome to the 2017 Meeting of the American Professional Society of ADHD and Related Disorders! APSARD is the premier, multidisciplinary, scientific organization in the US devoted to the advancement of both the science and clinical practices benefitting individuals with ADHD. This year’s theme, “From Science to Clinical Practice: ADHD Across the Lifespan” was chosen to highlight recent advances in basic, translational and clinical science on ADHD from preschool to college-age and beyond. The program is enriched with the very latest scientific advances as well as discussion of the latest (and some long-lasting) controversies relevant to ADHD.

The format includes state of the art plenaries, workshops, posters, and discussion groups led by internationally renowned scientists and clinicians. We also have special activities for young investigators/trainees and our international colleagues. Although APSARD has a large impact on the field of ADHD, we are relatively small as an organization.

I urge you to be active participant, and interact and network with other attendees, board members, and speakers. Also, please consider volunteering for APSARD committees throughout the year as we continue to grow the organization. These are exciting times for ADHD and for APSARD members. As we plan for next year’s meeting, we also invite you to provide feedback on the meeting and suggestions for next year.

Enjoy the conference and take advantage of the rich and varied cultural offerings of Washington DC!

With warm regards,

Mark Stein, PhD, ABPP
APSARD President
Welcome to the APSARD Annual Meeting

On behalf of the APSARD Annual Meeting Program Committee, we are delighted to welcome you to the 2017 APSARD Annual Meeting.

The conference will feature nationally and internationally renowned ADHD faculty who will share with participants recent research findings relevant to clinical practice.

2017 Program Highlights

- **Friday, January 13**
  - Welcome Reception with Poster Presentations – Including a Poster Tour with Faculty

- **Saturday, January 14**
  - Breakfast for Travel Awardees
  - *Meet the Editors (JAD)* Session
  - President’s Summary: *State of APSARD*
  - Plenary Sessions: *New Perspectives on the Neurobiology of ADHD and Understanding and Assessing Executive Function vs. Core Symptoms in Adult ADHD*
  - Symposium Sessions on Pre-school ADHD, College Students and ADHD, and Subthreshold ADHD
  - Workshop, *A Mindfulness Intervention for ADHD in Adulthood*
  - Poster Presentations at lunch – Including a Poster Tour with Faculty
  - Reception: With Faculty and Attendees

- **Sunday, January 15**
  - *Meet the Experts* Session
  - APSARD Business Meeting
  - Plenary Sessions, *Clinical and Epidemiological Studies of ADHD Across the Life Span: Does Age of Onset Matter? and Genetic and Environmental Factors in ADHD*
  - Symposia Sessions: *ADHD in Females and Stimulant vs Non-Stimulant Treatment of ADHD and Comorbidity*
  - Lunch Discussion Groups on *Understanding and Measuring Impairment and Sluggish Cognitive Tempo*

Organization

- **The meeting is sponsored by the American Society for ADHD and Related Disorders (APSARD).**
  - The Program Committee evaluates submitted proposals, develops program innovations, and invites speakers.
- **Parthenon Management Group organizes the APSARD Annual Meeting.**

The APSARD Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Most importantly, please join us and become a member if you are not already!

Best Regards,

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount Sinai
# TABLE OF CONTENTS

Meeting Space Maps ........................................ 5
Award Winners and Featured Speakers .................. 7
Acknowledgements ........................................... 21
Meeting Announcements .................................. 23
Friday, January 13, 2017 .................................. 29
Saturday, January 14, 2017 .............................. 33
Sunday, January 15, 2017 ................................ 43
Friday Posters ............................................. 51
Saturday Posters .......................................... 59
Author Index ............................................... 69
Notes ......................................................... 72

Disclosures for all APSARD presenters can be viewed at www.APSARD.org
Lifetime Achievement Award

Russell A. Barkley, Ph.D.
Medical University of South Carolina

Russell A. Barkley, Ph.D., is a Clinical Professor of Psychiatry at the Medical University of South Carolina. He is a Diplomate (board certified) in three specialties, Clinical Psychology (ABPP), Clinical Child and Adolescent Psychology, and Clinical Neuropsychology (ABCN, ABPP). Dr. Barkley is a clinical scientist, educator, and practitioner who has published 23 books, rating scales, and clinical manuals numbering 41 editions. He has also published more than 270 scientific articles and book chapters related to the nature, assessment, and treatment of ADHD and related disorders. He is the founder and Editor of the bimonthly clinical newsletter, The ADHD Report, now in its 20th year of publication. Dr. Barkley has presented more than 800 invited addresses internationally and appeared on nationally televised programs such as 60 Minutes, the Today Show, Good Morning America, CBS Sunday Morning, CNN, and many other programs on behalf of those with ADHD. He has received awards from the American Psychological Association, American Academy of Pediatrics, American Board of Professional Psychology, Association for the Advancement of Applied and Preventive Psychology, American Professional Society for ADHD and Related Disorders, New England Educational Institute, the Wisconsin Psychological Association, and Children and Adults with ADHD (CHADD) for his career accomplishments, contributions to research in ADHD, to clinical practice, and for the dissemination of science. His websites are www.russellbarkley.org and ADHDLectures.com.
AWARD WINNERS & FEATURED SPEAKERS

Recipients of the Best Paper in the Journal of Attention Disorders Award

Best Paper: Current Mood Symptoms Do Not Affect the Accuracy of Retrospective Self-Ratings of Childhood ADHD Symptoms

Katie Grogan¹, Jessica Bramham¹

¹University College Dublin, Ireland

Jessica Bramham, Ph.D.
University College Dublin, Ireland

Jessica Bramham is an Associate Professor in Clinical Neuropsychology at the School of Psychology, University College Dublin. As an undergraduate, she studied Natural Sciences at Cambridge University, then completed a Doctorate in Clinical Psychology followed by a Ph.D. in Neuropsychology at the Institute of Psychiatry, King’s College London. Jessica worked as a clinical psychologist in the Neuropsychiatry Department at the Maudsley Hospital and coordinated the UK National Adult ADHD Service. Jessica moved to University College Dublin in Ireland in January 2008 as a clinical academic. Her main research area is adulthood ADHD and its co-morbidities.
Recipients of the Best Paper in the
Journal of Attention Disorders Award

Katie Grogan, B.A.
University College Dublin, Ireland

Katie Grogan (B.A.) is a final year doctoral researcher and occasional lecturer at University College Dublin, under the supervision of Associate Professor, Jessica Bramham. Her Ph.D. research topic is entitled, ‘Why are adults with ADHD likely to develop anxiety disorders? An investigation of risk factors, measurement techniques, and impact on neuropsychological functioning’, and is funded by the Irish Research Council Government of Ireland Postgraduate Scholarship. She has published articles relating to adulthood ADHD and comorbidity in journals such as Journal of Attention Disorders and ADHD, and has presented at conferences such as the UK Adult ADHD Network’s (UKAAN) 4th Congress, London and the 5th World Congress of ADHD, Glasgow. Katie has also worked as a member of a multidisciplinary team at a specialist adult ADHD assessment clinic at St. Patrick’s University Hospital, Dublin since January 2015. She received training on adult ADHD diagnostic techniques by UKAAN in October 2016. Katie’s research interests focus on implementing recent empirical findings into clinical practice in a way that betters the diagnostic process and prognostic outcome for adults with ADHD.
AWARD WINNERS & FEATURED SPEAKERS

Travel Grant Awardees

Toral Desai, M.D.
University of Virginia

Heather Joseph, D.O.
University of Pittsburgh School of Medicine

Saniya Kibria, M.D.
New York - Presbyterian Hospital

John Leikauf, M.D.
Stanford University School of Medicine

Tyler Sasser, Ph.D.
Seattle Children’s Hospital

Monique Simpson, M.D.
Western Psychiatric Institute & Clinic/UPMC

Kayla Wagner, B.S.
Syracuse University

Travel Grant Alternates

Judith Fernando, M.D., M.P.H.
Dartmouth-Hitchcock Medical Center
Featured Speakers

Friday, January 13, 2017 from 5:30 PM – 7:00 PM

Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorders: Two Manifestations of One Overarching Disorder?

Jan Buitelaar, M.D., Ph.D.
Radboud Universiteit

Jan Buitelaar is a Professor of Psychiatry and Child and Adolescent Psychiatry at the Radboud University Medical Centre, and Principal Investigator at the Donders Institute for Brain, Cognition and Behavior in Nijmegen. He is also head of Karakter Child and Adolescent Psychiatry University Centre in Nijmegen. He has a strong clinical and research interest in neuropsychiatric disorders as ADHD, autism and impulsivity and aggression related disorders, and has been involved in pharmacological, cognitive, clinical, genetic, and neuroimaging studies in these disorders. His current active research is focused on translational studies aiming to identify new molecular targets for ADHD, autism, and aggression through matching preclinical models to human imaging genetics studies. He has published more than 650 peer-reviewed papers.
Friday, January 13, 2017 from 5:30 PM – 7:00 PM
Role of Metabotropic Glutamate Receptors (mGluRs) in the Etiology and Treatment of ADHD and Autism

Hakon Hakonarson, M.D., Ph.D.
Children’s Hospital of Philadelphia

Hakon Hakonarson, M.D., Ph.D., is Director of the Center for Applied Genomics and Professor of Pediatrics at The University of Pennsylvania, Perelman School of Medicine. Dr. Hakonarson received his M.D. and Ph.D. from the University of Iceland, School of Medicine. He leads a $40 million commitment from CHOP to genomically characterize approximately 100,000 children, an initiative that has gained nationwide attention in the *Wall Street Journal, New York Times, Time Magazine, Nature* and *Science*.

Dr. Hakonarson has previously held several senior posts within the biopharmaceutical industry, directing a number of genomics and pharmacogenomics projects as vice president of Clinical Sciences and Development at deCODE genetics, Inc. Dr. Hakonarson has been the principal investigator (PI) on several National Institute of Health-sponsored grants, and he was co-PI on the Neurodevelopmental Genomics: Trajectories of Complex Phenotypes, the largest project ever supported by the National Institute of Mental Health. Dr. Hakonarson recently completed a clinical biomarker study in ADHD demonstrating strong efficacy and safety of a neuromodulator compound in children with specific mutations in the glutamate metabotropic (mGluR) receptor family of genes (www.ClinicalTrial.gov).

Dr. Hakonarson has published over 500 scientific papers, including numerous high-impact papers on genomic discoveries and their translations in some of the most prestigious scientific medical journals, including *Nature, Nature Medicine, Nature Genetics, Cell* and *The New England Journal of Medicine*. *Time Magazine* listed Dr. Hakonarson’s autism gene discovery project, reported in *Nature* in 2009, among the top 10 medical breakthroughs of that year. With over 15 years of experience in pioneering genomics research and genome-wide mapping and association studies, Dr. Hakonarson has intimate knowledge of the complexities of large-scale genomics projects and has put together the necessary infrastructure and workflow processes to unravel these complexities.
Saturday, January 14, 2017 from 8:30 AM – 10:00 AM

Neuroscience of Mind Wandering

John Gabrieli, Ph.D.
Massachusetts Institute of Technology

John Gabrieli is the Director of the Athinoula A. Martinos Imaging Center at the McGovern Institute. He is an Investigator at the Institute, with faculty appointments in the Department of Brain and Cognitive Sciences and the Institute for Medical Engineering & Science, where he holds the Grover Hermann Professorship. He also has appointments in the Department of Psychiatry at Massachusetts General Hospital and the Harvard Graduate School of Education, and is the Director of the MIT Integrated Learning Initiative. Prior to joining MIT in 2005, he spent 14 years at Stanford University in the Department of Psychology and Neurosciences Program. He received a Ph.D. in Behavioral Neuroscience in the MIT Department of Brain and Cognitive Sciences and a B.A. in English from Yale University. In 2016 he was elected to the American Academy of Arts and Sciences.
Saturday, January 14, 2017 from 8:30 AM – 10:00 AM

*Neuroimaging of ADHD: Disorder-Specificity and Translation Into Neurotherapy*

**Katya Rubia, D. Phil.**  
King’s College London

Katya Rubia is Professor of Cognitive Neuroscience at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK, where she heads the Section of Developmental Neuroimaging at the Child & Adolescent Psychiatry Department. Prof. Rubia uses MRI to understand normal development of cognitive functions and their abnormalities in neurodevelopmental childhood disorders, most prominently in ADHD but also in autism, conduct disorder and obsessive-compulsive disorder and childhood abuse. She also investigates the effects of ADHD drugs on brain function, structure and neurochemistry using MRI and PET and has piloted fMRI-Neurofeedback as a novel neurotherapy for ADHD. Katya Rubia has published more than 180 papers in high impact journals, with an h-factor of 55. She obtained the Kramer-Pollnow Prize for her research in child psychiatry and is on the Editorial board of “Biological Psychiatry”, “Biological Psychiatry: Cognitive Neuroscience & Neuroimaging” and “ADHD.”
The World Health Organization Adult ADHD Self-Reporting Screening Scale (ASRS) for DSM-5

Ronald Kessler, Ph.D.
Harvard University

Ronald C. Kessler, Ph.D. is the McNeil Family Professor of Health Care Policy at Harvard Medical School.

Dr. Kessler’s research deals broadly with the social determinants of mental health and illness as studied from an epidemiological perspective. He is the author of over 600 publications and the recipient of many awards for his research, including the Senior Scientist and MERIT awards from the National Institute of Mental Health. He has been rated as the most widely cited researcher in the world in the field of psychiatry for each of the past fifteen years and is a member of both the Institute of Medicine and the National Academy of Sciences.

Dr. Kessler is the Principal Investigator of the U.S. National Comorbidity Survey, the first nationally representative survey of the prevalence and correlates of mental disorders in the U.S., and a Co-Director of the World Health Organization’s World Mental Health Survey Initiative, a series of comparative community epidemiological surveys of the prevalence and correlates of mental disorders and treatment for these disorders in 26 countries around the world. In addition to his epidemiological studies, Dr. Kessler is involved in evaluating a number of innovative programs for the prevention and treatment of mental illness in high-risk segments of the population. Finally, Dr. Kessler is the Principal Investigator of the Harvard Medical School site for STARRS-LS, a research program funded by the Department of Defense to study risk and protective factors for suicide among Army personnel.

Dr. Kessler earned his Ph.D. in sociology from New York University in 1975. He completed a postdoctoral fellowship in psychiatric epidemiology at the University of Wisconsin before joining the faculty at the University of Michigan in 1979. He was a Professor of Sociology and a Program Director at Michigan’s Institute for Social Research at the time he took his current position at Harvard Medical School in 1994.
Lenard Adler, M.D.
NYU School of Medicine

Lenard A. Adler, M.D. is the Director of the Adult ADHD Program in the Department of Psychiatry and Professor of Psychiatry and Child and Adolescent Psychiatry at the NYU School of Medicine. He obtained a B.A. in Economics from the College of Arts and Sciences at Cornell University in 1978. He earned his M.D. from Emory University School of Medicine in 1982, and completed his residency in Psychiatry in 1986 at NYU School of Medicine. He has been interviewed numerous times in national media venues, including 60 Minutes and the Today Show, as well as The New York Times, USA Today and U.S. News & World Report on Adult ADHD. He is an active investigator and frequent lecturer, who has authored and coauthored more than 130 peer-reviewed articles and book chapters. He is also author of the popular book on Adult ADHD: SCATTERED MINDS, G.P. Putnam’s Sons 2006 and co-editor of the textbook Attention-Deficit Hyperactivity Disorder in Children and Adults, Cambridge University Press 2015.
AWARD WINNERS & FEATURED SPEAKERS

Sunday, January 15, 2017 from 9:00 AM – 10:30 AM
ADHD From Childhood Through Adulthood:
Perspectives From a Population-Based Longitudinal Study

William Barbaresi, M.D.
Children’s Hospital, Boston

Dr. Barbaresi is the Wade Family Foundation Chair in Developmental Medicine, Director of the Developmental Medicine Center and Associate Chief of the Division of Developmental Medicine at Children’s Hospital Boston and Professor of Pediatrics at Harvard Medical School. He was formerly Associate Professor of Pediatrics at the College of Medicine, Mayo Clinic, Chair of the Division of Developmental and Behavioral Pediatrics at Mayo Clinic and Co-Director of the Mayo Clinic Dana Child Development and Learning Disorders Program. Dr. Barbaresi’s clinical practice includes children with developmental delays, mental retardation, autism spectrum disorders, attention-deficit/hyperactivity disorder, and learning disabilities, and behavior problems.

Dr. Barbaresi is a member of the American Board of Pediatrics, and past Chair of the Sub-Board for Developmental and Behavioral Pediatrics. He has held leadership positions in national organizations, including membership on the Board of Directors of the Society for Developmental and Behavioral Pediatrics. He is a member of the Editorial Board of the Journal of Developmental and Behavioral Pediatrics. He recently co-authored a report for the Institute of Medicine of the National Academy of Sciences on Speech and Language Disorders in Children.

Dr. Barbaresi’s research has included studies of the epidemiology of learning disorders, AD/HD and autism. He has authored numerous original scientific manuscripts, abstracts and book chapters on these topics He is continuing work as Principal Investigator of a National Institute of Mental Health funded study of long-term outcomes for children with AD/HD. He is the Director of Research for the national Developmental and Behavioral Pediatrics Research Network (DBPNet), funded by the Maternal and Child Health Bureau.
Sunday, January 15, 2017 from 9:00 AM – 10:30 AM
Sailing in Troubled Waters: New Findings on ADHD
Adolescent and Young Adult-Onset Trajectories and Their Childhood Predictors

Luis Rohde, M.D., Ph.D.
Federal University of Rio Grande do Sul

Luis A. Rohde, M.D., Ph.D. is Professor of Child and Adolescent Psychiatry in the Department of Psychiatry at the Federal University of Rio Grande do Sul, Brazil, Director of the Program for Attention-Deficit/Hyperactivity Disorder at the Hospital de Clinicas de Porto Alegre, and Vice-Coordinator of the National Institute of Developmental Psychiatry for Children and Adolescent, Brazil. He is currently Associate Editor of the Attention Deficit and Hyperactivity Disorder, International Editor of the Journal of the American Academy Child and Adolescent Psychiatry and former Co-Editor of the European Child and Adolescent Psychiatry.

He is President of the World Federation of ADHD, and was former Vice-President of the International Association of Child and Adolescent Psychiatry and Allied Professions.

Dr. Rohde’s research interests include ADHD epidemiology, genetics, pharmacogenetics, neuroimaging, and the effects of pharmacological and psychosocial treatments for ADHD. He has published extensively in peer review international and national journals (more than 250 papers), and has been an author or co-author in over 40 book chapters and editorials. He is editor or organizer of 8 books addressing child and adolescent mental health published in Brazil, UK, Germany and the US.
AWARD WINNERS & FEATURED SPEAKERS

Sunday, January 15, 2017 from 11:00 AM – 12:30 PM
The Biology of ADHD: From Basic Science to Application in the Clinic

Barbara Franke, Prof.
Radboud Universiteit

Barbara Franke is a Professor of Molecular Psychiatry at the Radboud University Medical Center and a Principal Investigator at the Donders Institute for Brain, Cognition and Behaviour in Nijmegen, The Netherlands. As a molecular biologist and geneticist, her research is focused on understanding the genetic contribution to (neurodevelopmental) psychiatric disorders, with a particular focus on ADHD. In addition to gene-finding approaches involving common and rare genetic variation, she uses bioinformatics, neuroimaging genetics, and small animal models to map biological pathways leading from gene to disease. She is the founder of the International Multicenter persistent ADHD Collaboration (IMpACT), a founding member and co-lead of the international ENIGMA Consortium on neuroimaging genetics, and the coordinator of several international consortia funded by the European Union, including the Aggressotype and MiND projects on ADHD comorbidity with aggression and autism. Barbara Franke has co-authored over 330 papers, her current H-factor is 64. She has received several prizes and awards, including Aspasia and Vici awards from the Netherlands Organization for Scientific Research (NWO) and the Radboud Hermesdorf International Prize 2013. For more information about her research and a full CV, please see http://www.ru.nl/people/donders/franke-b/.
Dr. Nigg obtained his A.B. at Harvard College, a Masters in Social Work at The University of Michigan, and Ph.D. in clinical Psychology at the University of California at Berkeley. Prior to obtaining his Ph.D. he worked for several years with youth in inner city Detroit, and then for several years as a clinician on an inpatient psychiatry unit. After obtaining his Ph.D. he was on the faculty at Michigan State University for 13 years. He is currently a Professor of Psychiatry and Behavioral Neuroscience and Director of the Division of Psychology at Oregon Health and Science University. He is a licensed psychologist who continues to co-direct an ADHD clinic. His research on ADHD has been supported by the National Institute of Mental Health continuously since 1998 and he was recently awarded a prestigious MERIT award from NIMH. He has published over 170 peer reviewed scientific papers in addition to numerous book chapters, editorials and reviews. His work has been cited over 10000 times. He is most recognized for his work on the neuropsychology of ADHD but he has also contributed in several other areas, most recently on gene and environment interplay.
ACKNOWLEDGEMENTS

Program Committee Members

Jeffrey Newcorn, M.D., Program Committee Chair
Icahn School of Medicine at Mount Sinai

Joseph Biederman, M.D.
Massachusetts General Hospital

Kathleen Nadeau, Ph.D.
Chesapeake ADHD Center of Maryland

Tanya Froehlich, M.D., MS
Cincinnati Children’s Hospital Medical Center

Luis Rohde, M.D.
Federal University of Rio Grande Do Sul

Scott Kollins, Ph.D.
Duke University

Thomas Spencer, M.D.
Massachusetts General Hospital

Frances Levin, M.D.
Columbia University Medical Center

John Tatarakis, M.P.H., M.S.
Department of Veterans Affairs

APSARD Officers and Board

Mark Stein, Ph.D., ABPP - President
Seattle Children’s Hospital

Stephen Faraone, Ph.D.
SUNY Upstate Medical University

Joseph Biederman, M.D.-
President Elect
Massachusetts General Hospital

Bob Findling, M.D., MBA
Johns Hopkins School of Medicine

Anthony Rostain, M.D., M.A. – Past President
University of Pennsylvania

Tanya Froehlich, M.D.
Cincinnati Children’s Hospital Medical Center

Betsy Busch, M.D., FAAP – Secretary
Tufts University School of Medicine

David Giwerc, MCC
ADHD Coach Academy

Vatsal Thakkar, M.D. - Treasurer
New York University School of Medicine

Sam Goldstein, Ph.D.
Journal of Attention Disorders

David Goodman, M.D.
Johns Hopkins School of Medicine
John Heiligenstein, M.D.
Pharmaceutical Industry

J.J. Sandra Kooij, M.D., Ph.D.
PsQ, Psycho-Medical Programs,
The Hague

Iris Manor, M.D.
Tel Aviv University

Greg Mattingly, M.D.
Washington University School of Medicine

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount Sinai

Andrew Nierenberg, M.D.
Massachusetts General Hospital

Russell Ramsay, Ph.D.
University of Pennsylvania

Mary Solanto, Ph.D.
New York University School of Medicine

Thomas Spencer, M.D.
Harvard Medical School

Craig Surman, M.D.
Massachusetts General Hospital

Roberta Waite, Ed.D
Drexel University

Rick Weisler, M.D.
University of North Carolina Chapel Hill School of Medicine

Margaret Weiss, M.D., Ph.D.
University of British Columbia Children and Women’s Health Centre
**Meeting Services**

**Registration Desk Hours:**
- Friday, January 13: 3:00 PM – 7:00 PM
- Saturday, January 14: 7:00 AM – 6:30 PM
- Sunday, January 15: 7:30 AM – 4:30 PM

*The registration/meeting information desk is located in the Promenade Foyer.

The APSARD Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 24 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Independence Meeting Room, Lower Level.
- Friday, January 13: 1:00 PM – 6:00 PM
- Saturday, January 14: 7:00 AM – 5:00 PM
- Sunday, January 15: 7:00 AM – 2:30 PM

**Americans with Disabilities Act** - It is the policy of APSARD not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3083 or send an email to info@apsard.org.

**APSARD Mobile App** - The APSARD mobile app is now available in the app store for iPhones and in Google Play for Androids. Search APSARD2017 and download today! View the latest schedule, attendee list and abstracts!
Continuing Education Credits

Continuing Education Credits are available for physicians, psychologists and nurses. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed after the conference at www.APSARD.org/meeting. Surveys for continuing education credit must be submitted no later than February 8, 2017.

Disclosures

Disclosures are available for all APSARD Annual Meeting presenters online at www.APSARD.org/meeting/program. It is the policy of the APSARD to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Accreditation Statements

This meeting is jointly sponsored by the American Professional Society of ADHD and Related Disorders and AMEDCO.

Continuing Education Credit Information:

CME Credit Statement:
Amedco designates this live activity for a maximum of 13 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Approval Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Amedco and the American Professional Society of ADHD & Related Disorders. Amedco is accredited by the ACCME to provide continuing medical education for physicians.
MEETING ANNOUNCEMENTS

Nursing Accreditation Statement:
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nursing Credit Designation Statement:
This course is co-provided by Amedco and the American Professional Society of ADHD & Related Disorders. Maximum of 13 contact hours.

APA Psychologists:
This course is co-sponsored by Amedco and Northeastern Society for Group Psychotherapy. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 13 hours.

Professional Counselors in these 41 states can submit APA:
AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL, IN, KS, ME, MO, MN, NC, ND, NH, NE, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

MFT’s in these 31 states can submit APA:
AK, AR, AZ, CA, CO, CT, DE, FL, IA, ID, IN, KS, ME, MO, NE, NC, NH, NM, NJ, NV, OK, OR, PA, SC, SD, TN, TX, UT, VA, WI, WY

Addiction Professional in these 26 states can submit APA:
AK, AR, CO, CT, DE, GA, IA, IN, KS, LA, MO, MT, NE, NM, NC, ND, NJ, NV, NY (outstate held), OK, OR, SC, UT, WA, WI, WY

ASWB Social Workers:
Amedco, #1346, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. Amedco maintains responsibility for the program. ASWB Approval Period: 06/24/2016– 06/24/2016. Social workers should contact their regulatory board to determine course approval for continuing education credits.

Social workers participating in this course may receive up to 13 clinical continuing education clock hours.
MEETING ANNOUNCEMENTS

Social Workers (continued):

Professional Counselors in these 30 states can submit ASWB:
AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, ME, MO, ND, NE, 
NM, NH, NV, OK, PA, TN, TX, UT, VA, WI, WY

MFT’s in these 25 states can submit ASWB:
AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, ME, MO, NC, NE, NH, NM, NV, OK, 
PA, TN, TX, UT, VA, WI, WY

Addictions Professionals in these 19 states can submit ASWB:
AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, 
WI, WV, WY

Satisfactory completion
Participants must complete an attendance/evaluation form to receive 
a certificate of completion/attendance. Your chosen sessions must be 
attended in their entirety. Partial credit of individual sessions is not available. 
All participants who request continuing education credits by February 
8, 2017, should expect to receive their statement of credits via email 
in March.

The Meeting Evaluation Survey will be available at www.APSPAR.org/
meeting. We encourage all registrants to complete the evaluation. 
Attendees requesting CME or CE credits must complete the survey in order 
to obtain credits. Your candid input on the 2017 meeting is appreciated as 
we strive to improve the meeting each year.
APSARD would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

Pfizer
Shire
Sunovion

APSARD Society Support
APSARD would like to thank the following sponsors for their generous donations to the society:

Platinum Sponsor:
Shire

Silver Sponsor:
Ironshore Pharmaceuticals & Development, Inc.

Bronze Sponsors:

Exhibitors
Please visit the exhibitors in the Promenade Foyer during the meeting.

- Arbor Pharmaceuticals
- CAADRA
- Duke Clinical Research Institute
- Genomind
- NEBA Health
- Qbtech
- Rhodes Pharmaceuticals
- Shire Pharmaceuticals
- Tris Pharmaceuticals
- The TOVA Company
- Vaya Pharmaceuticals
SCHEDULE AT A GLANCE

FRIDAY, JANUARY 13, 2017

3:00 PM – 7:00 PM  Registration Open
Promenade Foyer

3:00 PM – 5:00 PM  APSARD Board Meeting (By Invitation)
Senate

5:30 PM – 7:00 PM  Welcome and Opening Plenary Session:
ADHD and Autistic Spectrum Disorder. What Are the Relationships?
Grand Ballroom

7:00 PM – 8:30 PM  Reception and Poster Presentations with Poster Tours
East & State Ballroom
### FRIDAY, JANUARY 13, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM – 7:00 PM</td>
<td>Registration Open</td>
<td>Promenade Foyer</td>
</tr>
<tr>
<td>3:00 PM – 5:00 PM</td>
<td>APSARD Board Meeting (By Invitation)</td>
<td>Senate</td>
</tr>
<tr>
<td>5:30 PM – 7:00 PM</td>
<td>Welcome and Opening Plenary Session: ADHD and Autistic Spectrum Disorder. What Are the Relationships?</td>
<td>Grand Ballroom</td>
</tr>
</tbody>
</table>

**Chair:** Gagan Joshi, Harvard Medical School, Massachusetts General Hospital

*Role of Metabotropic Glutamate Receptors (mGluRs) in the Etiology and Treatment of ADHD and Autism*

Hakon Hakonarson, Children’s Hospital of Philadelphia and University of Pennsylvania

*Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: Two Manifestations of One Overarching Disorder?*

Jan Buitelaar, Radboud University Medical Center

**Overall Abstract:** There is frequent comorbidity of Autism Spectrum Disorder (ASD) and Attention-Deficit / Hyperactivity Disorders (ADHD), which are both neuropsychiatric and neurodevelopmental disorders. The high co-occurrence rates suggest that there is overlap of genetic factors, cognitive dysfunctions, and functional and structural brain characteristics. These talks will discuss the evidence for shared factors involved in both ASD and ADHD. One in particular is the role of metabotropic glutamate receptors, which has been noted to play a crucial role in many neurodevelopmental disorders. We will also cover current research, clinical significance, and future directions for research and treatment of ASD and ADHD.

**Learning Objectives:**
- Appreciate the high rates of Autism and ADHD co-occurrence and their shared genetic factors, cognitive dysfunctions, and functional and structural brain characteristics.
- Gain understanding of the role of metabotropic glutamate receptors in the etiology and treatment of ADHD and Autism.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PM – 8:30 PM</td>
<td><strong>Reception and Poster Presentations With Poster Tours</strong></td>
<td>East &amp; State Ballroom</td>
</tr>
<tr>
<td><strong>See pages 51 through 58 for Friday’s poster listings</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SCHEDULE AT A GLANCE

SATURDAY, JANUARY 14, 2017

7:00 AM – 6:00 PM  Registration Open
                        Promenade Foyer

7:00 AM – 8:00 AM  APSARD Travel Fellow Breakfast (By Invitation)
                        South Carolina

7:00 AM – 8:00 AM  Meet the JAD Editors Session
                        Grand Ballroom

7:30 AM – 8:30 AM  Morning Break
                        East & State Ballroom

8:15 AM – 8:30 AM  President’s Summary: State of APSARD
                        Grand Ballroom

8:30 AM – 10:00 AM  Plenary Session: New Perspectives on Neurobiology of ADHD
                        Grand Ballroom

10:00 AM – 10:30 AM  Coffee Break
                        East & State Ballroom

10:30 AM – 11:30 AM  Plenary Session: Understanding and Assessing Executive Function vs. Core Symptoms in Adult ADHD
                        Grand Ballroom

11:30 AM – 1:00 PM  Poster Session With Lunch and Poster Tours
                        East & State Ballroom

1:00 PM – 3:00 PM  Symposia Sessions

Are Subsyndromal Manifestations of Disorders Meaningful?
                      Grand Ballroom

ADHD in College Students
                      Chinese Ballroom

3:00 PM – 3:30 PM  Coffee Break
                        East & State Ballroom
### SCHEDULE AT A GLANCE

**Saturday, January 14, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM – 5:30 PM</td>
<td><strong>Concurrent Symposia/Workshop Sessions</strong></td>
</tr>
<tr>
<td></td>
<td><em>Current Issues and Mandates in Preschool ADHD</em></td>
</tr>
<tr>
<td></td>
<td><em>A Mindfulness Intervention for ADHD in Adulthood</em></td>
</tr>
<tr>
<td></td>
<td>Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td>Chinese Ballroom</td>
</tr>
<tr>
<td>5:30 PM – 6:00 PM</td>
<td><strong>Lifetime Achievement Award Presentation</strong></td>
</tr>
<tr>
<td></td>
<td>Grand Ballroom</td>
</tr>
<tr>
<td>6:00 PM – 7:00 PM</td>
<td><strong>Reception and Poster Viewing</strong></td>
</tr>
<tr>
<td></td>
<td>East &amp; State Ballroom</td>
</tr>
</tbody>
</table>
SATURDAY, JANUARY 14, 2017

7:00 AM – 6:00 PM  Registration Open
Promenade Foyer

7:00 AM – 8:00 AM  APSARD Travel Fellow Breakfast (By Invitation)
South Carolina

7:00 AM – 8:00 AM  Meet the JAD Editors Session
Grand Ballroom

7:30 AM – 8:30 AM  Morning Break
East & State Ballroom

8:15 AM – 8:30 AM  President’s Summary: State of APSARD
Grand Ballroom
Mark Stein, University of Washington

8:30 AM – 10:00 AM  Plenary Session: New Perspectives on Neurobiology of ADHD
Grand Ballroom

Chair: Jeffrey Newcorn, Icahn School of Medicine at Mount Sinai

Neuroimaging of ADHD, Disorder-Specificity and Translation Into Neurotherapy
Katya Rubia, King’s College London

Neurodiversity in Adult ADHD
John Gabrieli, Massachusetts Institute of Technology

Overall Abstract: This session will present results of studies using brain imaging to examine the multiplicity of brain regions and neural networks implicated in the pathophysiology of ADHD. It will consider similarities and differences in underlying neurobiology between ADHD and other disorders, and differences in neurobiology as a function of specific neuropsychological deficits, such as working memory. It will also examine the potential role of neurofeedback in attempting to modify regional activation and network function. Of considerable importance is the emerging role of the default mode network, the function of this region in relation to mind-wandering, and the coordinated relationship between default mode and task-positive network activity.
Learning Objectives:
• To understand results of studies examining the neurobiology of ADHD, and appreciate the multiplicity of brain regions implicated in the disorder.
• To understand the potential role of the default mode network to the pathophysiology of ADHD.
• To understand similarities and differences in underlying neurobiology between individuals with ADHD who have working memory deficits and those who do not.
• To appreciate the potential emerging role of neurofeedback in modifying brain network activity and thereby produce therapeutic improvement in individuals with ADHD.

10:00 AM – 10:30 AM  **Coffee Break**  
East & State Ballroom

10:30 AM – 11:30 AM  **Plenary Session: Understanding and Assessing Executive Function vs. Core Symptoms in Adult ADHD**  
Grand Ballroom

**Chair:** Lenard Adler, NYU School of Medicine

*Clinical Implications of Core Symptoms of Inattention and Hyperactivity/Impulsivity Vs. Executive Function (EF) and Emotional Control (EC) in Adult ADHD*
Lenard Adler, NYU School of Medicine

*The World Health Organization Adult ADHD Self-Reporting Screening Scale (ASRS) for DSM-5*
Ronald Kessler, Harvard University

**Overall Abstract:** This session will present recent findings as to the importance of core DSM symptoms of Inattention (IA) and Hyperactivity-Impulsivity (HI) vs. symptoms of Executive Function (EF) and Emotional Control (EC) in Adult ADHD. Data will be presented as to the loading and impact of these core symptoms and co-travelling symptoms of EF and EC. The session will also present data as to the development and validation of dsm-5 version of the Adult ADHD Self-Report Screener (ASRS Screener); psychometrics of this updated version of this screener will also be presented.
Learning Objectives:
• To discuss the importance of core symptoms of inattention and hyperactivity-impulsivity vs. the co-travelling symptoms of executive function and emotional control deficits.
• To understand the scoring and symptoms contained in the DSM-5 version of the ASRS Screener.

11:30 AM – 1:00 PM  
**Poster Session With Lunch and Poster Tours**  
East & State Ballroom  
**See pages 59 through 67 for Saturday’s poster listings**

Concurrent Symposia Sessions

1:00 PM – 3:00 PM  
**Are Subsyndromal Manifestations of Disorders Meaningful?**  
Grand Ballroom

Chair: Joseph Biederman, Massachusetts General Hospital

1:00 PM – 1:10 PM  
**Introduction**

1:10 PM – 1:30 PM  
*Subthreshold Psychosis Symptoms in the Philadelphia Neurodevelopmental Cohort*  
Raquel Gur, University of Pennsylvania

1:30 PM – 1:50 PM  
*The Consequences of Being Impaired but Undiagnosed*  
William Copeland, Duke University

1:50 PM – 2:10 PM  
*Similar Familial Underpinnings for Full and Subsyndromal Pediatric Bipolar Disorder: A Familial Risk Analysis*  
Stephen Faroone, SUNY Upstate Medical University

2:10 PM – 2:30 PM  
*Can Subsyndromal Manifestations of Major Depression Be Identified in Children at Risk?*  
Joseph Biederman, Massachusetts General Hospital

2:30 PM – 3:00 PM  
**Discussion**
**Overall Abstract:** This symposium will focus on ongoing efforts to assess the clinical and scientific relevance of subsyndromal manifestations of psychiatric disorders afflicting the young. Dr. Biederman investigated the utility of subsyndromal scores on the Child Behavior Checklist (CBCL) Anxiety/Depression scale in identifying children at the highest risk for pediatric MDD from among the pool of children of parents with MDD. Subsyndromal scores on the CBCL Anxiety/Depression scale significantly separated the children at high risk for pediatric MDD from those at low risk in a variety of functional areas, including social and academic functioning whereas children at genetic risk without elevated CBCL Anxiety/Depression scale scores were largely indistinguishable from controls. These results suggest that the CBCL Anxiety/Depression scale can help identify children at highest risk for pediatric MDD. Dr. Faraone used familial risk analysis to examine the validity of subthreshold pediatric bipolar-I (BP-I) disorder in child probands with full BP-I disorder, subthreshold BP-I disorder, ADHD, and healthy controls. Relatives of full BP-I and relatives of subthreshold BP-I probands had similarly elevated risk for BP-I disorder that were significantly higher than the rates in relatives of ADHD and relatives of control probands. These findings support the diagnostic continuity between subsyndromal and fully syndromatic states of pediatric BP-I disorder. Dr. Copeland’s presentation uses data from a prospective, population-based study of 1420 participants assessed with structured interviews up to 6 times in childhood (ages 9 to 16; 6674 observations) for subthreshold psychiatric problems. Participants were then assessed 4 times in young adulthood (ages 19, 21, and 25 and 30; 4556 observations of 1273 subjects) for psychiatric outcomes as well as functional outcomes. At any given childhood observation, 19-21% of the sample displayed significant impairment secondary to psychiatric symptoms but did not meet criteria for a psychiatric disorder. By age 16, 30-35% of children displayed symptomatic impairment while never meeting criteria for a well-specified adult disorder. This group was at increased risk of meeting criteria for an adult psychiatric disorder or displaying a critical outcome in adulthood. These results support the conclusion that the number of children affected by psychiatric symptoms is far greater than those that meet criteria for a psychiatric disorder. Such children are at risk for later psychiatric and functional problems even if they never meet full criteria for a childhood psychiatric disorder. Dr. Gur will present data on efforts at advancing early identification and intervention of subthreshold psychosis and concomitant underlying neurobiological processes. Using data from the Philadelphia Neurodevelopmental Cohort that evaluated ~ 10,000 genotyped youths age 8-21 years ascertained through a pediatric network at Children’s Hospital of Philadelphia. Subthreshold PS was noted in 12.3% of youths, age 11-
and was associated with other clinical features including depression and anxiety as well as cognitive deficits relative to typically developing (TD) youth, with most pronounced impairments on complex and social cognition domains. Multimodal neuroimaging showed that the PS group had a steeper decline in gray matter associated with development, impaired connectivity and diffusivity and aberrant pattern of fMRI activity during performance of a working memory and emotion recognition tasks: These alterations in brain-behavior measures evident early in the psychosis process can assist in early identification and intervention aimed at impacting developmental trajectories.

Learning Objectives:
• The audience will learn about the clinical and scientific importance of subthreshold diagnoses in pediatric psychiatry.
• The audience will learn about clinical examples of conditions in which a subthreshold diagnosis was specifically assessed.
• The audience will learn about the scientific and therapeutic implications of considering subthreshold diagnoses in practice.

1:00 PM – 3:00 PM  
**ADHD in College Students**  
Chinese Ballroom

**Chair:** Kevin Antshel, Syracuse University

1:00 PM – 1:10 PM  
Introduction

1:10 PM – 1:30 PM  
**ADHD Stigma and Malingering in College Students**  
Kevin Antshel, Syracuse University

1:30 PM – 1:50 PM  
**Longitudinal Outcome of College Students With ADHD**  
Arthur Anastopoulos, University of North Carolina at Greensboro

1:50 PM – 2:10 PM  
**Stimulant Diversion Among College Students With ADHD and the Primary Care-Provider Relationship**  
Brooke Molina, University of Pittsburgh

2:10 PM – 2:30 PM  
**Accommodations in College Students With ADHD**  
Larry Lewandowski, Syracuse University

2:30 PM – 3:00 PM  
Discussion
Overall Abstract: ADHD is a prevalent neurodevelopmental disorder that persists into adulthood. More than half of children with ADHD will attend a 2- or 4-year university, with prevalence rates of ADHD in college students estimated to be 5%. At least 25% of college students receiving disability services have ADHD. Thus, ADHD exists on college campuses. Despite ADHD existing in greater numbers on college campuses, our knowledge and understanding of ADHD in college students is relatively limited. This symposium brings together four clinical researchers who all have expertise in college students with ADHD. Individual talks will explore (a) understanding the longitudinal trajectory of ADHD in college and how best to intervene, (b) academic accommodations for college students with ADHD and what data and the law say about these accommodations, (c) stimulant medication misuse and diversion in college students with a focus on prevention within the primary care setting and (d) ADHD stigma and malingering in college students.

Learning Objectives:
• Increase participant understanding of how ADHD and its associated features and functional impairments unfold across the first four years of college, and are moderated/mediated by demographics and other variables of clinical interest.
• Understand opportunities for college student stimulant diversion prevention within the primary care setting.
• Understand current controversies in the provision of testing accommodations to college students with ADHD, making reference to relevant research where appropriate.
• Increase knowledge of associations between ADHD stigma and ADHD malingering in college students.

3:00 PM – 3:30 PM  Coffee Break
East & State Ballroom
Concurrent Symposia/Workshop Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM – 5:30 PM</td>
<td>Current Issues and Mandates in Preschool ADHD</td>
</tr>
<tr>
<td></td>
<td>Grand Ballroom</td>
</tr>
</tbody>
</table>

**Chair:** Scott Kollins, Duke University

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM – 3:40 PM</td>
<td>Introduction</td>
</tr>
<tr>
<td>3:40 PM – 4:05 PM</td>
<td>An Overview of Preschool ADHD: Developmental, Diagnostic, and Treatment Considerations</td>
</tr>
<tr>
<td></td>
<td>Scott Kollins, Duke University</td>
</tr>
<tr>
<td>4:05 PM – 4:30 PM</td>
<td>Longitudinal Trajectories of Preschool Children at Risk for ADHD: Factors Associated With Variability of Outcomes</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Halperin, Queens College</td>
</tr>
<tr>
<td>4:30 PM – 4:55 PM</td>
<td>Clinical Trials in Preschool ADHD: A Regulatory Perspective</td>
</tr>
<tr>
<td></td>
<td>Graciela Gonzalez and Tiffany Farchione, FDA</td>
</tr>
<tr>
<td>4:55 PM – 5:30 PM</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

**Overall Abstract:** ADHD is known to be a developmental disorder that emerges early in childhood, though there is controversy over how early the condition can be reliably diagnosed and the best approaches for treatment. This symposium will feature up-to-date information on the validity and reliability of ADHD diagnosis in preschool children, as well as what is known about safety and efficacy or both pharmacological and non-pharmacological treatments. We will also review data regarding how early behavioral and neurocognitive markers can predict outcomes later in life among young children at risk for ADHD. Finally, we will present a regulatory perspective on the importance of gathering data on the safety and efficacy of treatments in young children with ADHD.
Learning Objectives:
• Identify the primary treatment modalities with empirical support for managing ADHD in preschool aged children.
• Understand the developmental trajectories of young children at risk for ADHD and how they are related to clinical outcomes.
• Recognize the regulatory environment for approving treatments for preschool children with ADHD.

3:30 PM – 5:30 PM  A Mindfulness Intervention for ADHD in Adulthood  
Chinese Ballroom

John Mitchell, Duke University Medical Center

Overall Abstract: Mindfulness-Based Interventions (MBIs) involve the teaching of mindfulness meditation practices to target a variety of outcomes among different medical, psychiatric, and non-clinical populations. MBIs are particularly applicable for individuals with attention-deficit/hyperactivity disorder (ADHD) given that this treatment approach targets mechanisms that are also implicated in ADHD. Treatment outcome studies among adults diagnosed with ADHD demonstrate medium to large effect sizes for core symptoms and characteristic features of the disorder. There are currently few clinician materials to guide practitioners in administering an adapted MBI for adults diagnosed with ADHD. Therefore, the objectives of this workshop are to (a) define MBIs, (b) describe the rationale for applying MBIs to adults with ADHD, (c) establish the evidence-base of MBIs for ADHD, and (d) detail a MBI adapted for adults with ADHD: the Mindful Awareness Practices (MAPs) for ADHD Program. The latter will include a session-by-session description of the MAPs for ADHD Program.

Learning Objectives:
• Define mindfulness-based interventions (MBIs).
• Describe the rationale for applying MBIs to adults with ADHD.
• Establish the evidence-base of MBIs for ADHD in adulthood.
• Detail a MBI adapted for adults with ADHD.

5:30 PM – 6:00 PM  Lifetime Achievement Award Presentation, Russell Barkley, Ph.D.  
Grand Ballroom

6:00 PM – 7:00 PM  Poster Viewing and Reception  
East & State Ballroom
SCHEDULE AT A GLANCE

SUNDAY, JANUARY 15, 2017

7:30 AM – 3:00 PM  Registration Open
                   Promenade Foyer

7:00 AM – 8:00 AM  International Committee Breakfast and
                   Business Meeting (By Invitation)
                   Virginia

7:00 AM – 8:00 AM  Education and Social Media Committee
                   Meeting (By Invitation)
                   Senate

7:00 AM – 8:00 AM  Meet the Experts
                   Grand Ballroom

7:00 AM – 8:00 AM  Meet the Experts
                   Chinese Ballroom

7:30 AM – 8:30 AM  Morning Break
                   East & State Ballroom

8:15 AM – 9:00 AM  APSARD Business Meeting
                   Grand Ballroom

9:00 AM – 10:30 AM  Plenary Session: Clinical and Epidemiological
                     Studies of ADHD Across the Life Span: Does Age of Onset Matter?
                     Grand Ballroom

10:30 AM – 11:00 AM  Coffee Break
                     East & State Ballroom

11:00 AM – 12:30 PM  Plenary Session: Genetic and Environmental
                     Factors
                     Grand Ballroom

12:30 PM – 2:30 PM  Lunch Session and Poster Viewing
                     East & State Ballroom
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 PM – 2:00 PM</td>
<td><strong>Lunchtime Discussion Groups</strong></td>
<td></td>
<td><strong>Understanding and Measuring Impairment in ADHD</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grand Ballroom</td>
<td><strong>ADHD and Sluggish Cognitive Tempo: What Are the Data and What Are the Relationships?</strong></td>
</tr>
<tr>
<td>12:30 PM – 2:00 PM</td>
<td><strong>Meet the Experts</strong></td>
<td>Senate</td>
<td></td>
</tr>
<tr>
<td>12:30 PM – 2:00 PM</td>
<td><strong>Meet the Experts</strong></td>
<td>Cabinet</td>
<td></td>
</tr>
<tr>
<td>2:30 PM – 4:30 PM</td>
<td><strong>Symposia Sessions</strong></td>
<td></td>
<td><strong>Stimulant Vs. Nonstimulant Treatment of ADHD and Related Disorders</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grand Ballroom</td>
<td><strong>A Data-Driven Approach to Understanding ADHD in Females Across the Lifespan</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chinese Ballroom</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td><strong>Meeting Adjourns</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SUNDAY, JANUARY 15, 2017

7:00 AM – 8:00 AM  International Committee Breakfast and Business Meeting (By Invitation)
                   Virginia

7:00 AM – 8:00 AM  Education and Social Media Committee Meeting (By Invitation)
                   Senate

7:00 AM – 8:00 AM  Meet the Experts
                   Grand Ballroom

7:00 AM – 8:00 AM  Meet the Experts
                   Chinese Ballroom

7:30 AM – 3:00 PM  Registration Open
                   Promenade Foyer

7:30 AM – 8:30 AM  Morning Break
                   East & State Ballroom

8:15 AM – 9:00 AM  APSARD Business Meeting
                   Grand Ballroom

9:00 AM – 10:30 AM  Plenary Session: Clinical and Epidemiological Studies of ADHD Across the Life Span: Does Age of Onset Matter?
                    Grand Ballroom

Chair: Stephen Faraone, SUNY Upstate Medical University

ADHD From Childhood Through Adulthood: Perspectives From a Population-Based Longitudinal Study
William Barbaresi, HHMI, Children’s Hospital – Boston

Sailing in Troubled Waters: New Findings on ADHD Adolescent and Young Adult-Onset Trajectories and Their Childhood Predictors
Luis Rohde, Federal University of Rio Grande do Sul

Overall Abstract: This plenary session will present data to address recent claims that most cases of ADHD in childhood remit and that most cases of ADHD in adulthood are ‘adult onset’ cases. Several epidemiologic data sets will be presented along with discussion of the role of methodologic artifacts and the clinical implications of the findings.
Learning Objectives:
• Understand data about the persistence of ADHD from childhood into adulthood.
• Understand the basis of recent claims that most adult ADHD is ‘adult onset’ ADHD.
• Understand the methodological issues that weaken claims about adult onset ADHD.
• Understand the relevance of subthreshold youth disorders when evaluating ‘adult onset’ ADHD.

10:30 AM – 11:00 AM  Coffee Break  
East & State Ballroom

11:00 AM – 12:30 PM  Plenary Session: Genetic and Environmental Factors  
Grand Ballroom

Chair: Tanya Froehlich, Cincinnati Children’s Hospital Medical Center

The Biology of ADHD: From Basic Science to Application in the Clinic  
Barbara Franke, Radboud University Medical Center

ADHD and the Environment: Why and How Should We Study ADHD’s Environmental and Epigenetic Etiology?  
Joel Nigg, Oregon Health & Science University

Overall Abstract: If you want to stay on the cutting edge of understanding genetic and environmental contributions to ADHD, this session is for you. Dr. Barbara Franke will review genetic variants recently implicated in ADHD by genome-wide association and next generation sequencing studies. Next, through her discussion of neuroimaging genetics research, bioinformatics approaches, and animal models, Dr. Franke will show how the statistical definition of a link between genes and ADHD can promote a more biological understanding of the roles played by specific genes. Furthermore, Dr. Joel Nigg will discuss environmental contributions to ADHD etiology, including the importance of using causally and genetically informative designs in environmental studies. Moreover, Dr. Nigg will show how gene by environment interactions and epigenetic effects remain important—perhaps central—possibilities for much ADHD etiology, particularly for common (shared) environments.
Learning Objectives:
• Describe the contribution of genome-wide association, next generation sequencing, genetic neuroimaging, bioinformatics, and animal model approaches to understanding the genetic underpinnings of ADHD.
• Describe the use of epigenetic approaches, gene-environment interactions, and causally and genetically informative designs to elucidate the contribution of environmental factors to ADHD etiology.

12:30 PM – 2:00 PM  Lunch and Discussion Group: Understanding and Measuring Impairment in ADHD
                        Grand Ballroom

Facilitators:
Mark Stein, University of Washington
Margaret Weiss, University of Arkansas Medical Sciences

12:30 PM – 2:00 PM  Lunch and Discussion Group: ADHD and Sluggish Cognitive Tempo: What Are the Data and What Are the Relationships?
                        Chinese Ballroom

Facilitators:
Keith McBurnett, University of California, San Francisco
Tanya Froehlich, Cincinnati Children’s Hospital Medical Center

12:30 PM – 2:00 PM  Meet the Experts
                        Senate

12:30 PM – 2:00 PM  Meet the Experts
                        Cabinet
### Concurrent Symposia Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30 PM – 4:30 PM</td>
<td><strong>Stimulant Vs. Nonstimulant Treatment of ADHD and Related Disorders</strong></td>
<td>Grand Ballroom</td>
</tr>
</tbody>
</table>

**Chair:** Frances Levin, Columbia University Medical Center

- **2:30 PM – 2:40 PM**  
  **Introduction**

- **2:40 PM – 3:00 PM**  
  **Stimulants or Nonstimulants for ADHD: Comparative Effectiveness, Differential Response and Algorithm Development**  
  Jeffrey Newcorn, Icahn School of Medicine at Mount Sinai

- **3:00 PM – 3:20 PM**  
  **How Do We Best Treat Individuals With ADHD and Substance Use Disorders?**  
  Frances Levin, Columbia University Medical Center

- **3:20 PM – 3:40 PM**  
  **ADHD, Stimulants and Tics: Much Benefit, but How Much Risk?**  
  Barbara Coffey, Icahn School of Medicine at Mount Sinai

- **3:40 PM – 4:00 PM**  
  **Are There Different Effects of Stimulant and Non-Stimulants on Aggression in Patients With ADHD?**  
  Steven Pliszka, UT Health Science Center at San Antonio

- **4:00 PM – 4:30 PM**  
  **Discussion**

**Overall Abstract:** The large majority of youth with ADHD who are treated with psychostimulants have a significant reduction in symptoms, but a smaller number achieve normalized function. This presentation will review the mechanism of action of the different stimulant and nonstimulant medications for ADHD, and present clinical trials data that have examined comparative efficacy and effectiveness of the different medications. It will also examine data regarding relative efficacy of the different medications when given before or after other treatments, to inform on sequencing of treatments and the development of treatment algorithms.
Learning Objectives:
• To understand similarities and differences in mechanism of action of stimulant and non-stimulant medications for ADHD.
• To appreciate differences in comparative effectiveness between stimulant and nonstimulant medications for ADHD.
• To understand the relative impact of prior treatment on efficacy of the different medications.
• To understand the potential impact of comorbid aggression, tic disorders and substance abuse on treatment selection in individuals with ADHD.

2:30 PM – 4:30 PM  A Data-Driven Approach to Understanding ADHD in Females Across the Lifespan
Chinese Ballroom

Chair: Kathleen Nadeau, Chesapeake ADHD Center of Maryland

2:30 PM – 2:40 PM  Introduction

2:40 PM – 3:00 PM  Executive Dysfunction at Menopause: Behavioral and Imaging Correlates
Neill Epperson, University of Pennsylvania

3:00 PM – 3:20 PM  Eating Pathology Among Adolescent and Emerging Adult Women With ADHD
Amori Mikami, University of British Columbia

3:20 PM – 3:40 PM  Sexual Dimorphism in the Neurobehavioral Development of ADHD
Mark Mahone, Kennedy Krieger Institute

3:40 PM – 4:00 PM  Long Term Outcomes of Girls With ADHD: A Controlled Study
Joseph Biederman, Massachusetts General Hospital

4:00 PM – 4:30 PM  Discussion
Overall Abstract: ADHD exists within a context, be it neurological, maturational, social or hormonal and all of these various contexts have an impact upon the presentation of ADHD in females. This symposium will provide updates on the range of sex differences in ADHD that have been explored with presentations focusing on:

• Sex differences in the unfolding of ADHD symptom patterns related to striking differences in patterns of brain development
• Differences in social impairments in girls with ADHD in contrast to boys
• Hormonal changes in peri- and post-menopausal women that sometimes lead to a worsening of executive function (EF) in women
• Findings from a prospective, longitudinal study of girls with ADHD showing a much greater risk for a wide range of adverse psychiatric outcomes in young adulthood compared to girls without ADHD

Learning Objectives:
• Participants will be able to identify the elevated risk for multiple serious comorbid conditions as girls with ADHD enter young adulthood.
• Participants will be able to explain the differing patterns of neurological development in male and female brains and how these differences affect the presentation of ADHD at different developmental stages.
• Participants will be able to identify how changing hormonal levels in the brains of females can impact executive functioning.
• Participants will be able to explain how social problems in females with ADHD change from childhood, through adolescence and into adulthood.

4:30 PM  Meeting Adjourns
F1. Absence of Alignment of Symptom Response/Remission With Functional Outcomes in Children and Adolescents Following Treatment for ADHD
Margaret Weiss*, Ann Childress, Greg Mattingly, Earl Nordbrock, Robert J. Kupper, Akwete Adjei
1University of Arkansas Medical Sciences, 2Center for Psychiatry and Behavioral Medicine, Inc., 3Washington University School of Medicine
4Rhodes Pharmaceuticals L.P.

F8. Clinical Correlates of Working Memory Deficits in Non-Referred Youth With and Without ADHD: A Controlled Study
Ronna Fried*, Maura Fitzgerald, Sarah Kassabian, Joseph Biederman 1
1Massachusetts General Hospital & Harvard Medical School,
2Massachusetts General Hospital

F9. Examining the Association Between Attention Deficit Hyperactivity Disorder and Substance Use Disorders: A Familial Risk Analysis
Amy Yule*, MaryKate Martelon, Stephen Faraone, Nicholas Carrellas, Timothy Wilens, Joseph Biederman 1
1Harvard Medical School/Massachusetts General Hospital,
2Massachusetts General Hospital, 3SUNY Upstate Medical University & University of Bergen

F10. Abnormal Fear Circuitry in ADHD: A Controlled Magnetic Resonance Imaging Study
Joseph Biederman*, Andrea Spencer, Marie-France Marin, Mohammed R. Milad, Thomas Spencer
1Massachusetts General Hospital

F13. Nicotine-Induced Epigenetic Modification of Male Germline DNA is Associated With ADHD Phenotypes in the Offspring
Deirdre McCarthy*, Sarah Lowe, Thomas Morgan, Joseph Biederman, Thomas Spencer, Pradeep Bhide
1Center for Brain Repair, Florida State University College of Medicine,
2Florida State University, 3Massachusetts General Hospital & Harvard Medical School
F14. Reduced Subcortical Volumes in Preschoolers With ADHD
Keri Rosch*1, Deana Crocetti2, Stewart Mostofsky2, Mark Mahone2
1Kennedy Krieger Institute/Johns Hopkins, 2Kennedy Krieger Institute

F25. Efficacy and Safety of HLD200 in Children With Attention-Deficit/Hyperactivity Disorder: Results From a Pivotal Phase 3 Trial
Steven Pliszka*1, Valerie Arnold2, Andrea Marraffino3, Norberto DeSousa4, Bev Incledon4, F. Randy Sallee4, Timothy Wilens5, Jeffrey Newcorn6
1UT Health Science Center at San Antonio, 2CNS Healthcare/University of Tennessee, 3Florida Clinical Research Center, LLC, 4Ironshore Pharmaceuticals & Development, Inc., 5Harvard Medical School/Massachusetts General Hospital, 6Mount Sinai Medical Center

F26. DAT Occupancy Following Dasotraline Administration in Healthy Adult Subjects
Seth Hopkins*1, Robert Lew1, Georges El Fakhri2, Marc Normandin2, Anna Hall2, Barbara Storch2, Jennifer Wicks2, Dustin Wooten2, Kira Grogg2, Kenneth Koblan1, Thomas Spencer2
1Sunovion Pharmaceuticals, Inc., 2Massachusetts General Hospital

F27. Metadoxine Selectively Reverses Tonic and Phasic Gabaergic Transmission Deficits in the FMR1 Mouse Model
Johanna Schumann1, Jonathan Rubin*1, Yaron Daniely1, Amit Modgil2, Moss Stephen2
1Alcobra, Inc., 2Tufts University School of Medicine
POSTERS

Friday, January 13, 2017
7:00 PM – 8:30 PM
Reception and Poster Presentations

F1. Absence of Alignment of Symptom Response/Remission With Functional Outcomes in Children and Adolescents Following Treatment for ADHD
Margaret Weiss*, Ann Childress², Greg Mattingly³, Earl Nordbrock⁴, Robert J. Kupper⁴, Akwete Adjei⁴
¹University of Arkansas Medical Sciences, ²Center for Psychiatry and Behavioral Medicine, Inc., ³Washington University School of Medicine, Midwest Research Group, ⁴Rhodes Pharmaceuticals L.P.

F2. Sleep Patterns Among Children With ADHD and ASD Participating in a Summer Treatment Program: Preliminary Findings
Erin Underbrink*, Benjamin Aaronson², Tyler Sasser¹, Annette Estes², Mark Stein¹
¹Seattle Children’s Hospital, ²University of Washington

F3. Further Evidence of Morbidity and Dysfunction Associated With Subsyndromal ADHD in Clinically Referred Children
Maura Fitzgerald*, Joseph Biederman², Anna-Mariya Kirova¹, K. Yvonne Woodworth¹, Stephen Faroone³
¹Massachusetts General Hospital, ²Massachusetts General Hospital & Harvard Medical School, ³SUNY Upstate Medical University

F4. A Meta Analysis of ADHD and Increased Risk for Suicide
William Summers¹, Daniel Wendler¹, Tim Neary*¹
¹Northwest ADHD Treatment Center

F5. ADHD and Temperament
Toshinobu Takeda*, Yui Tsuji²
¹Ryukoku University, ²Health Sciences University of Hokkaido
F6. Clinically Analogous Dysregulation Behaviours in a Robotic Systems-Control Model of ADHD and Bipolar Disorder
Isaac Szpindel*1
1APSARD

F7. Practice Patterns of Primary Care Providers and Older ADHD Patients
Kerry Meyer*1, Patricia Read-Williams1, Tadd Hsie1, Jennifer Gibbs2, Moriah Stern3
1University of Washington, 2Baylor University, 3UW Neighborhood Clinic

F8. Clinical Correlates of Working Memory Deficits in Non-Referred Youth With and Without ADHD: A Controlled Study
Ronna Fried*1, Maura Fitzgerald2, Sarah Kassabian2, Joseph Biederman1
1Massachusetts General Hospital & Harvard Medical School, 2Massachusetts General Hospital

F9. Examining the Association Between Attention Deficit Hyperactivity Disorder and Substance Use Disorders: A Familial Risk Analysis
Amy Yule*1, MaryKate Martelon2, Stephen Faroone3, Nicholas Carrellas4, Timothy Wilens1, Joseph Biederman1
1Harvard Medical School/Massachusetts General Hospital, 2Massachusetts General Hospital, 3SUNY Upstate Medical University & University of Bergen, 4Massachusetts General Hospital

F10. Abnormal Fear Circuitry in ADHD: A Controlled Magnetic Resonance Imaging Study
Joseph Biederman*1, Andrea Spencer1, Marie-France Marin1, Mohammed R. Milad1, Thomas Spencer1
1Massachusetts General Hospital

F11. Impaired Frontal-Limbic White Matter Maturation in Children at Risk for Major Depression
Joseph Biederman*1, Yuwen Hung2, Zeynep Saygin2, Dina Hirshfeld-Becker1, Mai Uchida1, John Gabrielli2, Susan Whitfield-Gabrielli2
1Massachusetts General Hospital, 2Massachusetts Institute of Technology
POSTERS

F12. Nicotine-Induced Epigenetic Modification of Male Germline DNA is Associated With ADHD Phenotypes in the Offspring
Deirdre McCarthy*1, Sarah Lowe2, Thomas Morgan3, Joseph Biederman3, Thomas J. Spencer3, Pradeep Bhide1
1Center for Brain Repair, Florida State University College of Medicine, 2Florida State University, 3Massachusetts General Hospital & Harvard Medical School

F13. Reduced Subcortical Volumes in Preschoolers With ADHD
Keri Rosch*1, Deana Crocetti2, Stewart Mostofsky2, Mark Mahone2
1Kennedy Krieger Institute/Johns Hopkins, 2Kennedy Krieger Institute

Keri Rosch*1, Mary Beth Nebel2, Stewart Mostofsky2
1Kennedy Krieger Institute/Johns Hopkins, 2Kennedy Krieger Institute

F15. Abnormal Flow Patterns for Attention Deficit/Hyperactivity Disorder (ADHD)
Jonathan Posner2, Saniya Kibria*1
1New York - Presbyterian Hospital, 2New York State Psychiatric Institute

F16. Long Term Outcomes of Young Adults With 22q11DS and Comorbid ADHD
Lea Taylor*1, Yealim Chung1, Kayla Wagner1, Avery Albert1, Kevin Antshel1
1Syracuse University

F17. Factors Associated With Parental Evidence-Based Treatment-Seeking for Childhood ADHD
Lea Taylor*1, Samantha Mozden1, Avery Albert1, Kayla Wagner1, Kevin Antshel1
1Syracuse University
F18.  An Open-Label Trial of N-Acetylcysteine in the Treatment of Pediatric Bipolar Spectrum Disorders: An Interim Analysis

Rebecca Wolenski*, Maura Fitzgerald†, Joseph Biederman†, Stephen Faraone‡, Jacqueline Davis†, Janet Wozniak§
1Massachusetts General Hospital, 2SUNY Upstate Medical University, 3Massachusetts General Hospital & Harvard Medical School

F19.  Algorithm for Adult Attention Deficit Hyperactivity Disorder Management From the Psychopharmacology Algorithm Project at the Harvard South Shore Program.

Bushra Awidi*, David Osser
1VA Boston Healthcare System/Harvard Medical School, 2VA Boston Healthcare System

F20.  Are Stimulants Useful in the Management of Mild Traumatic Brain Injury?

Mary Iaccarino*, Lisa Philpotts‡, Ross Zafonte§, Joseph Biederman†
1Harvard Medical School, Massachusetts General Hospital, 2Treadwell Virtual Library, Massachusetts General Hospital, 3Harvard Medical School, Spaulding Rehabilitation Hospital

F21.  The Role of Hispanic Parents’ Negative Perceptions Relating to ADHD Treatment Outcomes

Julia Belfer‡, Lorena Wasersztein*
1University of Miami/Jackson Memorial Hospital, 2Nova Southeastern University

F22.  Preliminary Outcomes From an Innovative Community-Based Behavioral Health (BH) Program Serving Families Insured Through a Managed Medicaid Plan in Central Texas

Lindsey Warren Davis*, Mari-Ann Alexander†, Caron Farrell‡, Katrina Rodies§
1Dell Children’s Comprehensive Care Center, 2Seton Mind Institute, 3Austin Lakes Hospital
F23. Impact on the Family Unit of Early Morning Functional Impairments in Stimulant-Treated Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Russell Schachar*¹, Russell Barkley², Stephen Faraone³
¹University of Toronto, ²Medical University of South Carolina, ³SUNY Upstate Medical University

F24. Short & Long-Term Impact of a Nutritional Approach on ADHD Management: A Real World Study
Eran Ivanir*¹, Yael Richter¹, Gali Artzi¹, Carter Tate Holbrook², Robert Chudnow³, Amanda Gray³
¹Vaya Pharma, ²Children’s Health Services, ³Texas Child Neurology

F25. Efficacy and Safety of HLD200 in Children With Attention-Deficit/Hyperactivity Disorder: Results From a Pivotal Phase 3 Trial
Steven Pliszka*¹, Valerie Arnold², Andrea Marraffino³, Norberto DeSousa⁴, Bev Incledon⁴, F. Randy Sallee⁴, Timothy Wilens⁵, Jeffrey Newcorn⁶
¹UT Health Science Center at San Antonio, ²CNS Healthcare/University of Tennessee, ³Florida Clinical Research Center, LLC, ⁴Ironshore Pharmaceuticals & Development, Inc., ⁵Harvard Medical School/Massachusetts General Hospital, ⁶Mount Sinai Medical Center

F26. DAT Occupancy Following Dasotraline Administration in Healthy Adult Subjects
Seth Hopkins*¹, Robert Lew¹, Georges El FakhrI², Marc Normandin², Anna Hall², Barbara Storch², Jennifer Wicks², Dustin Wooten², Kira Grogg², Kenneth Koblan¹, Thomas Spencer²
¹Sunovion Pharmaceuticals, Inc., ²Massachusetts General Hospital

F27. Metadoxine Selectively Reverses Tonic and Phasic GABAergic Transmission Deficits in the FMR1 Mouse Model
Johanna Schumann¹, Jonathan Rubin*¹, Yaron Daniely¹, Amit Modgil², Moss Stephen²
¹Alcobra, Inc., ²Tufts University School of Medicine
F28. Open Board

F29. Dasotraline Enters the Brain More Slowly Than Methylphenidate in Rhesus Monkeys

Robert Lew*, Cristian Constantinescu², Vincent Carroll², Olivier Barret², Kenneth Koblan¹, Seth Hopkins¹
¹Sunovion Pharmaceuticals, Inc., ²Molecular NeuroImaging, A division of InviCRO
S1. Relationship Between the WRAADDS Symptom Rating of Inattention in Adults With ADHD and Performance in CDR Cognitive Tests in a Clinical Trial Population

Seth Hopkins*1, Robert Goldman1, Antony Loebel1, Kenneth Koblan1
1Sunovion Pharmaceuticals, Inc.

S4. Early Developmental Risk Factors for ADHD Symptoms in Young Children

Julia Schechter*1, Naomi Davis1, Bernard Fuemmeler2, Susan Murphy1, Cathrine Hoyo3, Scott Kollins1
1Duke University Medical Center, 2Virginia Commonwealth University, 3North Carolina State University

S5. Trait Anhedonia: A Risk Factor for Undetected Attention Deficit Hyperactivity Disorder and Suicide in Adult Depressed Patients

Tia Sternat*1, Kathryn Fotinos1, Alexa Fine1, Cathy Cameron1, Irvin Epstein1, Martin Katzman1
1START Clinic for Mood and Anxiety Disorders

S16. Treating Mothers First: Acceptability and Engagement in Pharmacological Treatment and Behavioral Parent Training for Mothers With ADHD

Erin Schoenfelder*1, Andrea Chronis-Tuscano2, Jennifer Strickland3, Elizabeth Bliss3, Daniel Almirall4, Mark Stein1
1University of Washington, 2University of Maryland, 3Seattle Children’s Research Institute, 4University of Michigan

S17. Medication Adherence in Pediatric and Young Adult Patients Prescribed ADHD Stimulants

Mancia Ko*1, Thomas Smith1
1Ingenuity Health, A Service of Ameritox, Ltd.

S18. Establishing Clinical Benefit of HLD200, a Novel Delayed-Release and Extended-Release Formulation of Methylphenidate, Using a Model-Based Approach

Roberto Gomeni*1, Stephen Faraone2, Thomas Spencer3, Bev Incledon4
1PharmacoMetrica, 2SUNY Upstate Medical University, 3Massachusetts General Hospital, 4Ironshore Pharmaceuticals & Development, Inc.
S19. **Daily Average Consumption (DACON) Among Commercially-Insured Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Who Received Monotherapy in the US**

Zhou Zhou², Zheng-Yi Zhou², Sneha Kelkar², Shang Li², Jipan Xie*², Regina Grebla¹

¹Formerly of Shire, ²Analysis Group, Inc.

S20. **The Efficacy and Safety of Amphetamine Extended-Release Oral Suspension (Amph Eros) in Children With ADHD**

Ann Childress*¹, Heidi W. Belden², Sally A. Berry²

¹Center for Psychiatry and Behavioral Medicine, Inc., ²Tris Pharma, Inc.
### S1. Relationship Between the WRAADDS Symptom Rating of Inattention in Adults With ADHD and Performance in CDR Cognitive Tests in a Clinical Trial Population

Seth Hopkins*, Robert Goldman¹, Antony Loebel¹, Kenneth Koblan¹  
¹Sunovion Pharmaceuticals, Inc.

### S2. The Concurrent Validity of the Barkley Functional Impairment Scale in Mothers With ADHD

Tyler Sasser*, Mark Stein²  
¹Seattle Children’s Hospital, ²University of Washington

### S3. How Informative Are Self Reports of Adults with ADHD for Monitoring Treatment in the Clinical Setting?: A Pilot Report Examining the Correspondence Between Clinician and Patient Assessments

Maura Fitzgerald*, Joseph Biederman², Thomas J. Spencer², Lenard Adler³, Jessica Abrams¹, K. Yvonne Woodworth⁷, Stephen Faraone⁴  
¹Massachusetts General Hospital, ²Massachusetts General Hospital & Harvard Medical School, ³NYU School of Medicine, ⁴SUNY Upstate Medical University

### S4. Early Developmental Risk Factors for ADHD Symptoms in Young Children

Julia Schechter*, Naomi Davis¹, Bernard Fuemmeler², Susan Murphy¹, Cathrine Hoyo³, Scott Kollins¹  
¹Duke University Medical Center, ²Virginia Commonwealth University, ³North Carolina State University

### S5. Trait Anhedonia: A Risk Factor for Undetected Attention Deficit Hyperactivity Disorder and Suicide in Adult Depressed Patients

Tia Sternat*, Kathryn Fotinos¹, Alexa Fine¹, Cathy Cameron¹, Irvin Epstein¹, Martin Katzman¹  
¹START Clinic for Mood and Anxiety Disorders
S6. Treatment Resistant Depression: A Depressive Phenotype of Attention Deficit Hyperactivity Disorder?

Tia Sternat*1, Alexa Fine1, Kathryn Fotinos1, Munira Mohamed1, Irvin Epstein1, Cathy Cameron1, Martin Katzman1
1START Clinic for Mood and Anxiety Disorders

S7. The Relationship Between Cognitive Distortions and ADHD After Accounting for Depression, Anxiety, and Personality Pathology

Amelia Serine*1, Brad Rosenfield2, Robert DiTomasso3
1Center for Brief Therapy, Philadelphia College of Osteopathic Medicine, 2ABCT, 3Philadelphia College of Osteopathic Medicine

S8. Persistence of DSM-5 ADHD Symptoms From Childhood to Adulthood Using Clinic Referred and PCP Office Based Samples

Lenard Adler*1, Michael J. Silvwerstein1, Samuel Alperin2, Saima Mili1, Terry L. Leon1, Oliver Pacifico1, Yonatan Hochstein1, Glenn S. Hirsch1, Stephen V. Faraone3, Ronald C. Kessler4
1NYU School of Medicine, 2Hofstra Northwell School of Medicine, 3SUNY Upstate Medical University, 4Harvard University

S9. Executive Function Deficits in Pediatric Obsessive-Compulsive Disorder and Attention-Deficit Hyperactivity Disorder: A Candidate Endophenotype for OCD?

Aamna Kabani*1, Audrey Chang1, Jeeva Jagabandhu1, Priyadurga Kodi1, Marco Grados1
1Johns Hopkins University School of Medicine

S10. Self Perceptions of Individuals With ADHD and Learning Disabilities and Their Post-Secondary Pathways

Avery Albert*1, Regina Conti2, Macy Warren2, Lea Taylor1, Kayla Wagner1, Kevin Antshel1
1Syracuse University, 2Colgate University
S11. Inattention and Hyperactivity-Impulsivity: Their Detrimental Effect on Romantic Relationship Maintenance
Kayla Wagner*1, Laura VanderDrift1, Amy Olszewski1, Lea Taylor1, Avery Albert1, Kevin Antshel1
1Syracuse University

S12. Actigraphically-Measured Sleep Disturbances and Impaired Executive Functioning in a Community Sample of Young Children
Jessica Lunsford-Avery*1, Julia Schechter1, Naomi Davis1, John Mitchell1, Bernard Fuemmeler2, Scott Kollins1
1Duke University Medical Center, 2Virginia Commonwealth University

S13. Collateral Reporters Use Relationship Strength and Patient Age to Gauge Mental Health Risks
Joel Young*1
1The Rochester Center for Behavioral Medicine

S14. Is Paternal Smoking at Conception a Risk for ADHD? A Controlled Study in Youth With and Without ADHD
Joseph Biederman*1, Maura Fitzgerald1, Thomas Spencer1, Pradeep Bhide2, Deirdre McCarthy3, K. Yvonne Woodworth1, Alexandra Saunders1, Stephen Faraone4
1Massachusetts General Hospital, 2Florida State University College of Medicine, 3Florida State University, 4SUNY Upstate Medical University & University of Bergen

S15. Atomoxetine-Related Change in Sluggish Cognitive Tempo is Largely Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms
Keith McBurnett*1, David Clemow2, David Williams3, Miguel Villodas4, Linda Wietecha2, Russell Barkley5
1University of California, San Francisco, 2Lilly USA, LLC, 3inVentive Health Clinical, 4Florida International University, 5Medical University of South Carolina
S16. Treating Mothers First: Acceptability and Engagement in Pharmacological Treatment and Behavioral Parent Training for Mothers With ADHD

Erin Schoenfelder*1, Andrea Chronis-Tuscano2, Jennifer Strickland3, Elizabeth Bliss3, Daniel Almirall4, Mark Stein1
1University of Washington, 2University of Maryland, 3Seattle Children’s Research Institute, 4University of Michigan

S17. Medication Adherence in Pediatric and Young Adult Patients Prescribed ADHD Stimulants

Mancia Ko*1, Thomas Smith1
1Ingenuity Health, A Service of Ameritox, Ltd.

S18. Establishing Clinical Benefit of HLD200, a Novel Delayed-Release and Extended-Release Formulation of Methylphenidate, Using a Model-Based Approach

Roberto Gomeni*1, Stephen Faraone2, Thomas Spencer3, Bev Incledon4
1PharmacoMetrica, 2SUNY Upstate Medical University, 3Massachusetts General Hospital, 4Ironshore Pharmaceuticals & Development, Inc.

S19. Daily Average Consumption (DACION) Among Commercially-Insured Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Who Received Monotherapy in the US

Zhou Zhou2, Zheng-Yi Zhou2, Sneha Kelkar2, Shang Li2, Jipan Xie*2, Regina Grebla1
1Formerly of Shire, 2Analysis Group, Inc.

S20. The Efficacy and Safety of Amphetamine Extended-Release Oral Suspension (Amph Eros) in Children With ADHD

Ann Childress*1, Heidi W. Belden2, Sally A. Berry2
1Center for Psychiatry and Behavioral Medicine, Inc., 2Tris Pharma, Inc.
S21. **Pooled Safety and Tolerability Data of Metadoxine Extended Release (MDX) From Three 6 Week Placebo Controlled Clinical Studies**

Pooled Safety and Tolerability Data of Metadoxine Extended Release (MDX) From Three 6 Week Placebo Controlled Clinical Studies

Eran Harary¹, Jonathan Rubin*¹, Natanya Slomowitz¹, Yaron Daniely¹, Lidia Gabis², Iris Manor³, Richard Weisler⁴
¹Alcobra, Inc., ²The Weinberg Child Development Center, ³Geha MHC, ⁴Duke University, UNC Chapel Hill, and Private Practice

S22. **MEASURE: A Phase 3 Placebo-Controlled Study of Metadoxine Extended Release in Adults With Attention Deficit Hyperactivity Disorder**

MEASURE: A Phase 3 Placebo-Controlled Study of Metadoxine Extended Release in Adults With Attention Deficit Hyperactivity Disorder

Jonathan Rubin*¹, Eran Harary¹, Natanya Slomowitz¹, Yaron Daniely¹, Lenard Adler², Jeffrey Newcorn³
¹Alcobra, Inc., ²NYU School of Medicine, ³Mount Sinai Medical Center

S23. **Dasotraline in Children With Attention Deficit Hyperactivity Disorder: Results of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study**

Dasotraline in Children With Attention Deficit Hyperactivity Disorder: Results of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study

Robert Goldman*¹, Lenard Adler², Thomas Spencer³, Robert Findling⁴, Seth Hopkins¹, Kenneth Koblan¹, Kaushik Sarma¹, Xiaohai Wan¹, Antony Loebel¹
¹Sunovion Pharmaceuticals, Inc., ²New York University Langone Medical Center, ³Massachusetts General Hospital, ⁴Kennedy Krieger Institute/Johns Hopkins University

S24. **Pharmacokinetics of a Novel Amphetamine Extended-Release Oral Suspension in Children With Attention-Deficit/Hyperactivity Disorder**

Pharmacokinetics of a Novel Amphetamine Extended-Release Oral Suspension in Children With Attention-Deficit/Hyperactivity Disorder

Carolyn Sikes*¹, Russ McMahen¹, Jeffrey Stark², Dorothy Engelking¹
¹Neos Therapeutics, ²Worldwide Clinical Trials
S25. Proof-Of-Concept Study Results of an Interactive Digital Treatment for Pediatric ADHD and Follow-Up Registration Study Design


1Meridien Research, 2Akili Interactive, 3SUNY Upstate Medical University, 4Alkermes, 5Duke University Medical Center

S26. Pharmacokinetics and Relative Bioavailability of an Extended-Release Chewable Tablet of Methylphenidate When Chewed Versus Swallowed Whole: A Pilot Study in Healthy Subjects

Richat Abbas*, Ann Childress, Praneeta Nagraj, Richard Rolke, Sally A. Berry, Donna Palumbo

1Pfizer, Inc., 2Center for Psychiatry and Behavioral Medicine, Inc., 3Tris Pharma, Inc.

S27. Dose Proportionality and Effect of Food on the Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults

Tao Liu*, Jogarao Gobburu, F. Randy Sallee, Angus McLean, Bev Incledon

1Center for Translational Medicine, School of Pharmacy, University of Maryland Baltimore, 2Ironshore Pharmaceuticals & Development, Inc.

S28. Clinical Response and Symptomatic Remission With MPH-MLR (Methylphenidate Extended-Release) in Children and Adolescents With ADHD

Greg Mattingly*, Ann Childress, Earl Nordbrock, Akwete Adjei, Robert J. Kupper, Margaret Weiss

1St. Charles Psychiatric Associates, 2Center for Psychiatry and Behavioral Medicine, Inc., 3Rhodes Pharmaceuticals L.P., 4University of Arkansas Medical Sciences


Heidi W. Belden, Sally A. Berry*

1Tris Pharma, Inc.
S30. Efficacy and Safety of Modified-Release Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder in Routine Clinical Care: Results From the Idea Study

Markus Gleitz*1, Michael Rösler2, Wolfgang Retz3
1MEDICE Arzneimittel Pütter GmbH, 2Saarland University Hospital, Institute for Forensic Psychology and Psychiatry, 3University Medicine of the Johannes Gutenberg-University
AUTHOR INDEX

Aaronson, Benjamin 53
Abbas, Richat 66
Abrams, Jessica 61
Adjei, Akwete 51, 53, 66
Adler, Lenard 16, 36, 61, 62, 65
Albert, Avery 55, 62, 63
Alexander, Mari-Ann 56
Almirall, Daniel 59, 64
Alperin, Samuel 62
Anastopoulos, Arthur 39
Antshel, Kevin 39, 55, 62, 63
Arnold, Valerie 52, 57
Arzi, Gali 57
Awidi, Bushra 56
Barbaresi, William 17, 45
Barkley, Russell 7, 42, 57, 63
Barret, Olivier 58
Belden, Heidi W. 60, 64, 66
Belfer, Julia 56
Berry, Sally A. 60, 64, 66
Bhide, Pradeep 51, 55, 63
Biederman, Joseph 21, 37, 49, 51, 53, 54, 55, 61, 63
Bliss, Elizabeth 59, 64
Bower, Jeffrey D. 66
Bramham, Jessica 8
Buitelaar, Jan 11, 31
Busch, Betsy 21
Cameron, Cathy 59, 61, 62
Carrellas, Nicholas 51, 54
Carroll, Vincent 58
Chang, Audrey 62
Childress, Ann 51, 53, 60, 64, 66
Chronis-Tuscano, Andrea 59, 64
Chudnow, Robert 57
Chung, Yealim 55
Clemow, David 63
Coffey, Barbara 48
Constantinescu, Cristian 58
Conti, Regina 62
Copeland, William 37
Crocetti, Deana 52, 55
Cutler, Andrew 66
Daniely, Yaron 52, 57, 58, 65
Davis, Jacqueline 56
Davis, Lindsey Warren 56
Davis, Naomi 59, 61, 63, 66
Desai, Toral 10
DeSousa, Norberto 52, 57
DiTomaso, Robert 62
El Fakhri, Georges 52, 57
Engelking, Dorothy 65
Epperson, Neill 49
Epstein, Irvin 59, 61, 62
Estes, Annette 53
Faraone, Stephen 21, 37, 45, 51, 53, 54, 56, 57, 59, 61, 62, 63, 64, 66
Farchione, Tiffany 41
Farrell, Caron 56
Fernando, Judith 10
Findling, Robert 21, 65
Fine, Alexa 59, 61, 62
Fitzgerald, Maura 51, 53, 54, 56, 61, 63
Fotinos, Kathryn 59, 61, 62
Franke, Barbara 19, 46
Fried, Ronna 51, 54
Froehlich, Tanya 21, 46, 47
Fuemmeler, Bernard 59, 61, 63
Gabis, Lidia 65
Gabrieli, John 13, 35, 54
Gibbs, Jennifer 54
Giwerc, David 21
Gleitz, Markus 67
Gobburu, Jogarao 66
Goldman, Robert 59, 61, 65
Goldstein, Sam 21
Gomeni, Roberto 59, 64
Gonzalez, Graciela 41
Goodman, David 21
Grados, Marco 62
Gray, Amanda 57
Grebla, Regina 60, 64
Grogan, Katie 8, 9
Grogg, Kira 52, 57
Gur, Raquel 37
Hakonarson, Hakon 12, 31
Hall, Anna 52, 57
Halperin, Jeffrey 41
Harary, Eran 65
Heal, David J 58
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heiligenstein, John</td>
<td>22</td>
</tr>
<tr>
<td>Hirsch, Glenn S.</td>
<td>62</td>
</tr>
<tr>
<td>Hirshfeld-Becker, Dina</td>
<td>54</td>
</tr>
<tr>
<td>Hochstei, Yonatan</td>
<td>62</td>
</tr>
<tr>
<td>Holbrook, Carter Tate</td>
<td>57</td>
</tr>
<tr>
<td>Hopkins, Seth</td>
<td>52, 57, 58, 59, 61, 65</td>
</tr>
<tr>
<td>Hoyo, Cathrine</td>
<td>59, 61</td>
</tr>
<tr>
<td>Hsie, Tadd</td>
<td>54</td>
</tr>
<tr>
<td>Hung, Yuwen</td>
<td>54</td>
</tr>
<tr>
<td>Iaccarino, Mary</td>
<td>56</td>
</tr>
<tr>
<td>Incledon, Bev</td>
<td>52, 57, 59, 64, 66</td>
</tr>
<tr>
<td>Ivanir, Eran</td>
<td>57</td>
</tr>
<tr>
<td>Jagabandhu, Jeeva</td>
<td>62</td>
</tr>
<tr>
<td>Joseph, Heather</td>
<td>10</td>
</tr>
<tr>
<td>Joshi, Gagan</td>
<td>31</td>
</tr>
<tr>
<td>Kabani, Aamna</td>
<td>62</td>
</tr>
<tr>
<td>Kassabian, Sarah</td>
<td>51, 54</td>
</tr>
<tr>
<td>Katzman, Martin</td>
<td>59, 61, 62</td>
</tr>
<tr>
<td>Kelkar, Sneha</td>
<td>60, 64</td>
</tr>
<tr>
<td>Kellogg, Scott</td>
<td>66</td>
</tr>
<tr>
<td>Kessler, Ronald</td>
<td>15, 36, 62</td>
</tr>
<tr>
<td>Kibria, Saniya</td>
<td>10, 55</td>
</tr>
<tr>
<td>Kirova, Anna-Mariya</td>
<td>53</td>
</tr>
<tr>
<td>Ko, Mancia</td>
<td>59, 64</td>
</tr>
<tr>
<td>Koblan, Kenneth</td>
<td>52, 57, 58, 59, 61, 65</td>
</tr>
<tr>
<td>Kodi, Priyadurga</td>
<td>62</td>
</tr>
<tr>
<td>Kollins, Scott</td>
<td>21, 41, 59, 61, 63, 66</td>
</tr>
<tr>
<td>Kooij, J.J. Sandra</td>
<td>22</td>
</tr>
<tr>
<td>Kupper, Robert J.</td>
<td>51, 53, 66</td>
</tr>
<tr>
<td>Leikauf, John</td>
<td>10</td>
</tr>
<tr>
<td>Leon, Terry L.</td>
<td>62</td>
</tr>
<tr>
<td>Levin, Frances</td>
<td>21, 48</td>
</tr>
<tr>
<td>Lewandowski, Larry</td>
<td>39</td>
</tr>
<tr>
<td>Lew, Robert</td>
<td>52, 57, 58</td>
</tr>
<tr>
<td>Li, Shang</td>
<td>60, 64</td>
</tr>
<tr>
<td>Liu, Tao</td>
<td>66</td>
</tr>
<tr>
<td>Loebel, Antony</td>
<td>59, 61, 65</td>
</tr>
<tr>
<td>Lowe, Sarah</td>
<td>51, 55</td>
</tr>
<tr>
<td>Lunsford-Avery, Jessica</td>
<td>63</td>
</tr>
<tr>
<td>Mahone, Mark</td>
<td>49, 52, 55</td>
</tr>
<tr>
<td>Manor, Iris</td>
<td>22, 65</td>
</tr>
<tr>
<td>Marin, Marie-France</td>
<td>51, 54</td>
</tr>
<tr>
<td>Marraffino, Andrea</td>
<td>52, 57</td>
</tr>
<tr>
<td>Martelon, MaryKate</td>
<td>51, 54</td>
</tr>
<tr>
<td>Martucci, W. Edward</td>
<td>66</td>
</tr>
<tr>
<td>Mattingly, Greg</td>
<td>22, 51, 53, 66</td>
</tr>
<tr>
<td>McBurnett, Keith</td>
<td>47, 63</td>
</tr>
<tr>
<td>McCarth, Deirdre</td>
<td>51, 55, 63</td>
</tr>
<tr>
<td>McLean, Angus</td>
<td>66</td>
</tr>
<tr>
<td>McMahan, Russ</td>
<td>65</td>
</tr>
<tr>
<td>Meyer, Kerry</td>
<td>54</td>
</tr>
<tr>
<td>Mikami, Amori</td>
<td>49</td>
</tr>
<tr>
<td>Milad, Mohammed R.</td>
<td>51, 54</td>
</tr>
<tr>
<td>Mili, Saima</td>
<td>62</td>
</tr>
<tr>
<td>Mitchell, John</td>
<td>42, 63</td>
</tr>
<tr>
<td>Modgil, Amit</td>
<td>52, 57</td>
</tr>
<tr>
<td>Mohamed, Munira</td>
<td>62</td>
</tr>
<tr>
<td>Molina, Brooke</td>
<td>39</td>
</tr>
<tr>
<td>Morgan, Thomas</td>
<td>51, 55</td>
</tr>
<tr>
<td>Mostofsky, Stewart</td>
<td>52, 55</td>
</tr>
<tr>
<td>Mozden, Samantha</td>
<td>55</td>
</tr>
<tr>
<td>Murphy, Susan</td>
<td>59, 61</td>
</tr>
<tr>
<td>Nadeau, Kathleen</td>
<td>21, 49</td>
</tr>
<tr>
<td>Nagraj, Praneeta</td>
<td>66</td>
</tr>
<tr>
<td>Neary, Tim</td>
<td>53</td>
</tr>
<tr>
<td>Nebel, Mary Beth</td>
<td>55</td>
</tr>
<tr>
<td>Newcorn, Jeffrey</td>
<td>21, 22, 35, 48, 52, 57, 65</td>
</tr>
<tr>
<td>Nierenberg, Andrew</td>
<td>22</td>
</tr>
<tr>
<td>Nigg, Joel</td>
<td>20, 46</td>
</tr>
<tr>
<td>Nordbrock, Earl</td>
<td>51, 53, 66</td>
</tr>
<tr>
<td>Normandin, Marc</td>
<td>52, 57</td>
</tr>
<tr>
<td>Northcutt, Joanne L.</td>
<td>66</td>
</tr>
<tr>
<td>Olszewski, Amy</td>
<td>63</td>
</tr>
<tr>
<td>Osser, David</td>
<td>56</td>
</tr>
<tr>
<td>Pacifico, Oliver</td>
<td>62</td>
</tr>
<tr>
<td>Palumbo, Donna</td>
<td>66</td>
</tr>
<tr>
<td>Philpotts, Lisa</td>
<td>56</td>
</tr>
<tr>
<td>Pliszka, Steven</td>
<td>48, 52, 57</td>
</tr>
<tr>
<td>Posner, Jonathan</td>
<td>55</td>
</tr>
<tr>
<td>Ramsay, Russell</td>
<td>22</td>
</tr>
<tr>
<td>Read-Williams, Patricia</td>
<td>54</td>
</tr>
<tr>
<td>Retz, Wolfgang</td>
<td>67</td>
</tr>
<tr>
<td>Richter, Yael</td>
<td>57</td>
</tr>
<tr>
<td>Rodies, Katrina</td>
<td>56</td>
</tr>
<tr>
<td>Rohde, Luis</td>
<td>18, 21, 45</td>
</tr>
<tr>
<td>Rolke, Richard</td>
<td>66</td>
</tr>
<tr>
<td>Rosch, Keri</td>
<td>52, 55</td>
</tr>
<tr>
<td>Rosenfield, Brad</td>
<td>62</td>
</tr>
<tr>
<td>Rösler, Michael</td>
<td>67</td>
</tr>
<tr>
<td>Rostain, Anthony</td>
<td>21</td>
</tr>
<tr>
<td>Rubia, Katya</td>
<td>14, 35</td>
</tr>
<tr>
<td>Author Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Rubin, Jonathan</td>
<td>52, 57, 58, 65</td>
</tr>
<tr>
<td>Sallee, F. Randy</td>
<td>52, 57, 66</td>
</tr>
<tr>
<td>Sarma, Kaushik</td>
<td>65</td>
</tr>
<tr>
<td>Sasser, Tyler</td>
<td>10, 53, 61</td>
</tr>
<tr>
<td>Saunders, Alexandra</td>
<td>63</td>
</tr>
<tr>
<td>Saygin, Zeynep</td>
<td>54</td>
</tr>
<tr>
<td>Schachar, Russell</td>
<td>57</td>
</tr>
<tr>
<td>Schechter, Julia</td>
<td>59, 61, 63</td>
</tr>
<tr>
<td>Schoenfelder, Erin</td>
<td>59, 64</td>
</tr>
<tr>
<td>Schumann, Johanna</td>
<td>52, 57, 58</td>
</tr>
<tr>
<td>Serine, Amelia</td>
<td>62</td>
</tr>
<tr>
<td>Sikes, Carolyn</td>
<td>65</td>
</tr>
<tr>
<td>Silwserstein, Michael J.</td>
<td>62</td>
</tr>
<tr>
<td>Simpson, Monique</td>
<td>10</td>
</tr>
<tr>
<td>Slomowitz, Natanya</td>
<td>65</td>
</tr>
<tr>
<td>Smith, Thomas</td>
<td>59, 64</td>
</tr>
<tr>
<td>Solanto, Mary</td>
<td>22</td>
</tr>
<tr>
<td>Spencer, Andrea</td>
<td>51, 54</td>
</tr>
<tr>
<td>Spencer, Thomas</td>
<td>21, 22, 51, 52, 54, 55, 57, 59, 61, 63, 64</td>
</tr>
<tr>
<td>Stark, Jeffrey</td>
<td>65</td>
</tr>
<tr>
<td>Stein, Mark</td>
<td>21, 35, 47, 53, 59, 61, 64</td>
</tr>
<tr>
<td>Stephen, Moss</td>
<td>52, 57</td>
</tr>
<tr>
<td>Sternat, Tia</td>
<td>59, 61, 62</td>
</tr>
<tr>
<td>Stern, Moriah</td>
<td>54</td>
</tr>
<tr>
<td>Storch, Barbara</td>
<td>52, 57</td>
</tr>
<tr>
<td>Strickland, Jennifer</td>
<td>59, 64</td>
</tr>
<tr>
<td>Summers, William</td>
<td>53</td>
</tr>
<tr>
<td>Surman, Craig</td>
<td>22</td>
</tr>
<tr>
<td>Szpindel, Isaac</td>
<td>54</td>
</tr>
<tr>
<td>Takeda, Toshinobu</td>
<td>53</td>
</tr>
</tbody>
</table>
Become an APSARD Member Today!

Visit www.APSARD.org for details!